Kala Pharma Sees Unexpected Reaction to FDA Approval
Kala Pharmaceuticals shares dipped on Thursday after the U.S. Food and Drug Administration (FDA) announced that it had approved INVELTYS (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares dipped on Thursday after the U.S. Food and Drug Administration (FDA) announced that it had approved INVELTYS (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.
In most cases an FDA approval would help boost the stock, but this seems to be a case of sell the news for Kala Pharma.
What separates INVELTYS from the rest is that it is a twice-daily (BID) ocular corticosteroid, while all other ocular steroids are only approved for four-times-a-day dosing. This more frequent dosing requirement can lead to issues for both doctors and patients.
Separately, Kala is continuing to advance KPI-121 0.25% for dry eye disease. The company has initiated a third Phase 3 clinical trial, STRIDE 3 (STRIDE – Short Term Relief In Dry Eye), evaluating KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
[nativounit]
Kim Brazzell, Ph.D., Chief Medical Officer of Kala, commented on the approval:
The FDA approval of INVELTYS is a tremendous milestone for Kala. Approximately 8 million patients undergo ocular surgeries each year. The approval of INVELTYS offers patients and their eye care professionals the first and only BID ocular corticosteroid therapy that has been shown in clinical trials to be clinically effective while maintaining a proven safety profile, which may improve compliance and prove less burdensome for patients. We believe INVELTYS will be an important addition to eye care professionals’ treatment armamentarium.
Shares of Kala were last seen down about 4% at $12.98, with a consensus analyst price target of $30.80 and a 52-week range of $11.39 to $26.75.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
